Market Overview

UPDATE: Raymond James Upgrades Becton, Dickinson & Company from Underperform to Market Perform

Share:
Related BDX
Benzinga's Top Upgrades
UBS Upgrades Becton Dickinson To Buy
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

In a research note published Wednesday, Raymond James upgraded Becton, Dickinson and Company (NYSE: BDX) from Underperform to Market Perform.

The firm's Lawrence Keusch noted Becton, Dickinson and Company's business has stabilized and this is reflected in the solid Q1 results.

Keusch also believes that shares of BDX will perform inline with the market citing a valuation reflecting improved fundamentals and numerous defensive qualities in its business profile, which are likely to be favored in the current equity market.

BDX's shares are currently up 0.77 percent trading around $106.71.

Latest Ratings for BDX

DateFirmActionFromTo
Jul 2015BarclaysReinstatesEqual-weight
Jun 2015UBSUpgradesBuy
Mar 2015Goldman SachsReinstatesNeutral

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (BDX)

Get Benzinga's Newsletters